LT3003284T - Hif hidroksilazės inhibitoriaus farmacinės kompozicijos - Google Patents

Hif hidroksilazės inhibitoriaus farmacinės kompozicijos

Info

Publication number
LT3003284T
LT3003284T LTEP14735770.1T LT14735770T LT3003284T LT 3003284 T LT3003284 T LT 3003284T LT 14735770 T LT14735770 T LT 14735770T LT 3003284 T LT3003284 T LT 3003284T
Authority
LT
Lithuania
Prior art keywords
pharmaceutical formulations
hydroxylase inhibitor
hif hydroxylase
hif
inhibitor
Prior art date
Application number
LTEP14735770.1T
Other languages
English (en)
Inventor
David CONCA
Lee Flippin
Scott Leigh
Claudia WITSCHI
Lee Wright
Original Assignee
Fibrogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3003284(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen, Inc. filed Critical Fibrogen, Inc.
Publication of LT3003284T publication Critical patent/LT3003284T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP14735770.1T 2013-06-06 2014-06-05 Hif hidroksilazės inhibitoriaus farmacinės kompozicijos LT3003284T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
LT3003284T true LT3003284T (lt) 2020-04-27

Family

ID=51063834

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14735770.1T LT3003284T (lt) 2013-06-06 2014-06-05 Hif hidroksilazės inhibitoriaus farmacinės kompozicijos

Country Status (24)

Country Link
US (3) US20160120859A1 (lt)
EP (2) EP3708154A1 (lt)
JP (4) JP6604941B2 (lt)
KR (3) KR102291860B1 (lt)
CN (5) CN111728952A (lt)
AU (1) AU2014274890B2 (lt)
CA (1) CA2914049C (lt)
CY (1) CY1122951T1 (lt)
DK (1) DK3003284T3 (lt)
ES (1) ES2786924T3 (lt)
HK (1) HK1222550A1 (lt)
HR (1) HRP20200615T1 (lt)
HU (1) HUE049623T2 (lt)
IL (3) IL298998B1 (lt)
LT (1) LT3003284T (lt)
ME (1) ME03777B (lt)
MX (3) MX2015016536A (lt)
PL (1) PL3003284T3 (lt)
PT (1) PT3003284T (lt)
RS (1) RS60464B1 (lt)
SG (1) SG11201509764RA (lt)
SI (1) SI3003284T1 (lt)
WO (1) WO2014197660A1 (lt)
ZA (1) ZA201508712B (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
HUE034409T2 (en) 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
EP2872488B1 (en) 2012-07-16 2018-08-22 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3708154A1 (en) 2013-06-06 2020-09-16 Fibrogen, Inc. Pharmaceutical formulations of a hif hydroxylase inhibitor
MX2017012460A (es) * 2015-04-01 2018-01-30 Akebia Therapeutics Inc Composiciones y metodos para el tratamiento de la anemia.
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
WO2019042641A1 (en) * 2017-09-04 2019-03-07 Sandoz Ag CO-CRYSTAL OF A HIF PROLYL HYDROXYLASE INHIBITOR AVAILABLE ORALLY
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
CN115279342A (zh) * 2020-03-17 2022-11-01 兹杜斯生命科学有限公司 包含hif脯氨酰羟化酶抑制剂的制剂
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN114796280A (zh) * 2022-06-15 2022-07-29 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) * 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
UA84694C2 (ru) 2002-12-16 2008-11-25 Киссеи Фармасьютикал Ко., Лтд. Капсула для лечения дизурии, содержащая гранулиновое индолиновое соединение - блокатор -адренорецепторов
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US20070042937A1 (en) 2003-08-01 2007-02-22 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
KR101194123B1 (ko) 2004-03-16 2012-10-24 아사히 가세이 파마 가부시키가이샤 패수딜 함유 제제 및 그 안정성을 개선하는 방법
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
JP5166876B2 (ja) 2005-10-31 2013-03-21 興和株式会社 光安定性に優れた医薬製剤
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP2044028B1 (en) 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
RS51330B (en) * 2006-02-09 2011-02-28 Teva Pharmaceutical Industries Ltd. STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODIUM
AU2007218051A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
WO2007115315A2 (en) 2006-04-04 2007-10-11 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
ES2377426T3 (es) 2007-10-12 2012-03-27 Astrazeneca Ab Composición de zibotentán que contiene manitol y celulosa microcristalina
US20110039878A1 (en) 2007-11-02 2011-02-17 Volkmar Guenzler-Pukall Methods for reducing blood pressure
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009075824A1 (en) 2007-12-06 2009-06-18 Fibrogen, Inc. Methods for increasing endothelial progentior cells
WO2009075826A1 (en) 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
EP2341904A1 (en) 2008-08-26 2011-07-13 Fibrogen, Inc. Methods for treatment of multiple sclerosis
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
KR20110117133A (ko) 2009-01-29 2011-10-26 다이닛본 스미토모 세이야꾸 가부시끼가이샤 내핵을 갖는 구강 내 붕괴 정
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
CN103429239A (zh) 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
US20140057941A1 (en) 2011-01-13 2014-02-27 Kin-Hung (Peony) Yu Methods For Increasing Mean Corpuscular Volume
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
KR102029951B1 (ko) 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
WO2013070908A1 (en) 2011-11-09 2013-05-16 Fibrogen, Inc. Therapeutic method
AU2013229922B2 (en) 2012-03-09 2017-09-28 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2872488B1 (en) 2012-07-16 2018-08-22 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
HUE034409T2 (en) 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
EP3708154A1 (en) 2013-06-06 2020-09-16 Fibrogen, Inc. Pharmaceutical formulations of a hif hydroxylase inhibitor

Also Published As

Publication number Publication date
CN111728952A (zh) 2020-10-02
CN105377242A (zh) 2016-03-02
HRP20200615T1 (hr) 2020-07-10
SG11201509764RA (en) 2015-12-30
JP2023068197A (ja) 2023-05-16
MX2022011225A (es) 2022-10-07
CN110448537A (zh) 2019-11-15
BR112015029693A8 (pt) 2019-12-24
AU2014274890A1 (en) 2015-12-17
JP2021100971A (ja) 2021-07-08
HUE049623T2 (hu) 2020-09-28
US20160120859A1 (en) 2016-05-05
ME03777B (me) 2021-04-20
WO2014197660A1 (en) 2014-12-11
DK3003284T3 (da) 2020-03-30
RU2015151056A3 (lt) 2018-05-03
IL242759B2 (en) 2023-05-01
US10765672B2 (en) 2020-09-08
IL242759B1 (en) 2023-01-01
CY1122951T1 (el) 2021-10-29
EP3003284A1 (en) 2016-04-13
KR102291860B1 (ko) 2021-08-20
AU2014274890B2 (en) 2019-10-03
RU2681304C2 (ru) 2019-03-06
ZA201508712B (en) 2020-07-29
IL296484A (en) 2022-11-01
CN111728950A (zh) 2020-10-02
JP2019137703A (ja) 2019-08-22
CA2914049C (en) 2021-10-12
BR112015029693A2 (pt) 2017-07-25
US20220054474A1 (en) 2022-02-24
JP2016523846A (ja) 2016-08-12
KR20220164069A (ko) 2022-12-12
RS60464B1 (sr) 2020-07-31
MX2015016536A (es) 2016-08-11
EP3708154A1 (en) 2020-09-16
ES2786924T3 (es) 2020-10-14
CN111728951A (zh) 2020-10-02
EP3003284B1 (en) 2020-02-12
JP6861758B2 (ja) 2021-04-21
CA2914049A1 (en) 2014-12-11
IL298998A (en) 2023-02-01
IL298998B1 (en) 2024-03-01
RU2015151056A (ru) 2017-07-14
PT3003284T (pt) 2020-08-10
KR20210104173A (ko) 2021-08-24
NZ714554A (en) 2021-06-25
PL3003284T3 (pl) 2020-08-10
MX2020003096A (es) 2020-08-17
JP6604941B2 (ja) 2019-11-13
US20190008846A1 (en) 2019-01-10
SI3003284T1 (sl) 2020-08-31
IL242759A (lt) 2015-12-31
KR20160018514A (ko) 2016-02-17
NZ754196A (en) 2021-06-25
HK1222550A1 (zh) 2017-07-07

Similar Documents

Publication Publication Date Title
HK1222550A1 (zh) 羥化酶抑制劑的藥物製劑
IL285528A (en) A process for preparing a pde4 inhibitor
HUE061252T2 (hu) Lizinspecifikus demetiláz-1 inhibítorok
HK1248217A1 (zh) 選擇性cdk4/6抑制劑的固態形式
HK1206743A1 (en) 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors hif 4--
IL264259A (en) Oral formulations of pyrrolidine derivatives
HK1220125A1 (zh) 拉喹莫德的透皮配方
HK1204916A1 (en) Pharmaceutical application of anhydroicaritin
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
PL2801352T3 (pl) Ulegające rozpadowi w jamie ustnej formulacje lakozamidu
GB201320835D0 (en) HIF inhibitors
EP3052475A4 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile